Merge Medical Startup Podcast

Merge Medical Startup Podcast

di Dr. Jeff Cole and Dr. Jeff Brown
InvestimentiMedicina
Stagione 2

VITEL HEALTH: Deep Dive Podcast

Healthcare has been criticized for its slow adoption of advanced technology, and independent doctors can lag even further behind the curve due to the reasonable fear of the financial, security, and administrative risks associated with implementing new and unproven technologies such as AI, digital therapeutics, and remote vital sign monitoring. The healthcare technology landscape is littered with vendors who don’t always have the physician or patient best-interest in mind. “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Brittany Busse, Co-Founder of ViTel Health. ViTel Health is a technology platform-as-a-service company that is empowering physicians to thrive in independent practice by creating and vetting technology solutions that are proven to improve the lives of physicians and the patients they in their care. ViTel Health was founded by Dr. Brittany Busse and Doug Sumaraga in 2021 with the mission “Happy Physicians, Healthy Patients.” Our current “sick care” system has taken the autonomy of physicians, left us burned out, and has decimated the care of patients. ViTel Health is using technology to turn the sick care system to healthcare system and partnering physicians with health coaches who can offer consistent support to patients struggling with chronic disease. It’s more than Remote Physiologic Monitoring, it’s Tech Enabled Health Coaching, and it gets results. Patients are healthier, staying out of the hospital, and physician practices are thriving with the extra revenue combined with limited administrative work. ViTel Health has created a simple vertically-integrated solutions that handles all of the compliance, hiring, documentation, and billing associated with this billable service, empowering doctors to take better care of patients and earn extra revenue. Beyond cutting edge RPM/CCM services, ViTel Health and the ViTel Health Physician Services Cooperative are committed to empowering the return of the independent physician practice in the US. Our services include an affordable and flexible EHR, cost effective credentialing/contracting, revenue cycle management, malpractice, legal advice, and more. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E28
13 feb 2024
1:13:36

VITEL HEALTH: 10 in 10 Podcast

Healthcare has been criticized for its slow adoption of advanced technology, and independent doctors can lag even further behind the curve due to the reasonable fear of the financial, security, and administrative risks associated with implementing new and unproven technologies such as AI, digital therapeutics, and remote vital sign monitoring. The healthcare technology landscape is littered with vendors who don’t always have the physician or patient best-interest in mind. “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Brittany Busse, Co-Founder of ViTel Health. ViTel Health is a technology platform-as-a-service company that is empowering physicians to thrive in independent practice by creating and vetting technology solutions that are proven to improve the lives of physicians and the patients they in their care. ViTel Health was founded by Dr. Brittany Busse and Doug Sumaraga in 2021 with the mission “Happy Physicians, Healthy Patients.” Our current “sick care” system has taken the autonomy of physicians, left us burned out, and has decimated the care of patients. ViTel Health is using technology to turn the sick care system to healthcare system and partnering physicians with health coaches who can offer consistent support to patients struggling with chronic disease. It’s more than Remote Physiologic Monitoring, it’s Tech Enabled Health Coaching, and it gets results. Patients are healthier, staying out of the hospital, and physician practices are thriving with the extra revenue combined with limited administrative work. ViTel Health has created a simple vertically-integrated solutions that handles all of the compliance, hiring, documentation, and billing associated with this billable service, empowering doctors to take better care of patients and earn extra revenue. Beyond cutting edge RPM/CCM services, ViTel Health and the ViTel Health Physician Services Cooperative are committed to empowering the return of the independent physician practice in the US. Our services include an affordable and flexible EHR, cost effective credentialing/contracting, revenue cycle management, malpractice, legal advice, and more. ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E27
13 feb 2024
19:02

MedCoShare: Deep Dive Podcast

Loss of autonomy is one of the strongest factors leading to physician burnout and exits from medicine. Are you ready to practice on your own schedule? Interested in a cost-effective hybrid practice with a mix of in-person and virtual patient care visits? Satellite offices? Reality check…long term leasing of real estate makes this impossible.   “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Greg Goldmacher (Co-Founder) and Ronak Vyas (CEO) of MedCoShare.     MedCoShare is combining co-working space with additional services within a fully scalable membership model that starts with one half day per week and a one-month commitment. Premium support services include ordering of supplies, office staffing and practice marketing. MedCoShare plans to make additional bolt-on services available in 2024-25. These targeted services include billing, revenue cycle management, credentialing, and more.   Whether you are part of a sizable group or in solo practice, the MedCoShare membership model makes practicing the way you like a reality. It makes opening a satellite office (or two) cost-effective.   MedCoShare has moved well beyond the proof-of-concept stage and has its eye on a national growth strategy. This innovative, flexible, and affordable co-working model is currently available in Pennsylvania and New Jersey. Fresh, modern spaces are planned for more locations on the East Coast, as well as other parts of the US in 2024-25.   ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E26
5 feb 2024
41:06

MedCoShare: 10 in 10 Podcast

Loss of autonomy is one of the strongest factors leading to physician burnout and exits from medicine. Are you ready to practice on your own schedule? Interested in a cost-effective hybrid practice with a mix of in-person and virtual patient care visits? Satellite offices? Reality check…long term leasing of real estate makes this impossible.   “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Dr. Greg Goldmacher (Co-Founder) and Ronak Vyas (CEO) of MedCoShare.     MedCoShare is combining co-working space with additional services within a fully scalable membership model that starts with one half day per week and a one-month commitment. Premium support services include ordering of supplies, office staffing and practice marketing. MedCoShare plans to make additional bolt-on services available in 2024-25. These targeted services include billing, revenue cycle management, credentialing, and more.   Whether you are part of a sizable group or in solo practice, the MedCoShare membership model makes practicing the way you like a reality. It makes opening a satellite office (or two) cost-effective.   MedCoShare has moved well beyond the proof-of-concept stage and has its eye on a national growth strategy. This innovative, flexible, and affordable co-working model is currently available in Pennsylvania and New Jersey. Fresh, modern spaces are planned for more locations on the East Coast, as well as other parts of the US in 2024-25.   ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E25
5 feb 2024
19:57

LUMOS: Deep Dive Podcast

Sleep is a wonderful thing…if, and when, you can count on it. The sleep aid business is projected to reach $118B by 2030. Why? Very few things treat the root cause. Will Lumos revolutionize the sleep industry through the ability to strengthen and modulate circadian rhythms, the foundation of sleep? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Biquan Luo, Ph.D. (CEO and Co-Founder) and Kyle Pfaffenbach, Ph.D. (Performance Nutrition Specialist) of Lumos. Lumos was founded by Stanford scientists specializing in regulating human circadian rhythms, Lumos offers a sleep solution for everyone via its smart sleep mask, cell phone app and patented technology. The positive effects of science-based algorithms for jet lag, sleep disruptions caused by night shifts and everyday falling asleep and staying asleep have been demonstrated by robust clinical studies funded by the US military. Lumos is poised to significantly impact quality of sleep on a large scale with its low COG, cost-effective solution. Might you want to own a small piece of this company whose science is two decades in the making? ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured. ​
S2 · E24
30 gen 2024
53:55

LUMOS: 10 in 10 Podcast

Sleep is a wonderful thing…if, and when, you can count on it. The sleep aid business is projected to reach $118B by 2030. Why? Very few things treat the root cause. Will Lumos revolutionize the sleep industry through the ability to strengthen and modulate circadian rhythms, the foundation of sleep? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Biquan Luo, Ph.D. (CEO and Co-Founder) and Kyle Pfaffenbach, Ph.D. (Performance Nutrition Specialist) of Lumos. Lumos was founded by Stanford scientists specializing in regulating human circadian rhythms, Lumos offers a sleep solution for everyone via its smart sleep mask, cell phone app and patented technology. The positive effects of science-based algorithms for jet lag, sleep disruptions caused by night shifts and everyday falling asleep and staying asleep have been demonstrated by robust clinical studies funded by the US military. Lumos is poised to significantly impact quality of sleep on a large scale with its low COG, cost-effective solution. Might you want to own a small piece of this company whose science is two decades in the making? ***** Would this bring value to you, your family or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E23
30 gen 2024
16:20

TRIFLO CARDIOVASCULAR: Deep Dive Podcast

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular. Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population. Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population. First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E22
12 gen 2024
45:38

TRIFLO: 10 in 10 Podcast

By going back to the drawing board, has this global team of founders solved for tricuspid regurgitation, the “forgotten valve”? How far will they advance this breakthrough solution before one of the 4 major cardiovascular giants want to own it? “10 in 10” or quick-hitting version of our video podcast. Drs Jeff Brown and Jeff Cole interview Frank Ahmann of Triflo Cardiovascular. Tricuspid regurgitation (TR) affects millions of elderly patients and is associated with a significant decrease of quality of life, increased hospitalizations, and impaired survival. Symptomatic severe TR is grossly under-treated. The current leading transcatheter technologies only address a limited segment of the patient population. Southern California - based Triflo Cardiovascular is developing the Tricuspid Flow Optimizer, a minimally invasive valve specifically ideated for TR. The minimalistic design includes an adaptive mini valve and single size transfemoral delivery system. The Optimizer works in tandem with the native valve regardless of its size and shape therefore treating a broader patient population. First successful clinical cases have been completed indicating that the device not only reduces regurgitation, but also supports the global cardiac recovery to improve function, exercise capacity, and quality of life. Triflo Cardiovascular is gearing up to expand clinical studies and move towards future regulatory approval. They are preparing to raise a Series B round of funding. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2 · E21
13 gen 2024
11:59

NEURALITY HEALTH AI: Deep Dive Podcast

Take the demo for a spin. It’s set up as a dentistry practice, so you can role-play scheduling an appointment. Challenge the AI by asking tough questions or even making inappropriate statements—things that would test your best staff members. You’ll be amazed by its professionalism, natural voice inflections, and overall performance. And there’s more to it than just that. In this episode of the Merge Medical Deep Dive Podcast, Drs. Jeff Brown and Jeff Cole speak with Rahul Sharma, co-founder and CEO of Neurality Health. Neurality Health AI streamlines the administrative and operational tasks of both the front and back office using human-like voice and text. The AI handles inbound calls, schedules appointments, educates patients, and enhances engagement through recall and reactivation programs. It also verifies insurance benefits, manages payer communications, and has the potential to take on other revenue cycle management (RCM) responsibilities. Neurality Health’s onboarding process also includes several proprietary and AI-enhanced processes allowing them to add pilot practices and paying customers quickly and with ease. Their sales are reaching an inflection point where some might even say they are “exploding” to the upside. The company is rapidly expanding from its initial focus on dentistry into multiple medical subspecialties. Founded by seasoned health tech entrepreneurs and AI experts, Neurality Health is addressing key pain points faced by clinicians. With a track record of success and a focus on continued innovation, Neurality Health is poised to become the AI operating system of the future for healthcare. Investment and strategic partner opportunities: Neurality Health quickly closed a $350K pre-seed round largely funded by subject matter experts and customers within their initial target market of dentistry. They have opened an add-on pre-seed round also structured as a Y-Combinator SAFE note at a compelling valuation of $5M. Strategic partners and investors have been identified within several medical specialties such as ENT and orthopedic surgery. This offering is capped at $500K and may be filled by the time of this publication. ***** Would this bring value to you or your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S2
7 ott 2024
47:29
Stagione 1

SOMAVAC: Deep Dive Podcast

Is surgical drain management worthy of disruption? SOMAVAC is launching a deep tissue negative pressure device for large flaps (mastectomies and hernia repairs). FDA cleared for seroma prevention. Benefits to the patient & hospital/payor undeniable? “Deep Dive” or uncut version of our video podcast. Drs Jeff Brown and Jeff Cole interview Esra Roan, PhD and Jane Berz, RN, MSN of SOMAVAC, an early-revenue company launching a deep tissue Negative Pressure Therapy device for large flaps created by plastic and general surgeries such as mastectomies and hernia repairs. The internationally patented SOMAVAC SVS delivers constant negative pressure therapy to effectively remove fluids and hold tissue layers together. The device is FDA cleared for seroma prevention. Early studies indicate earlier removal of surgical drains, which is known to correlate with infection rates, and overall fewer complications when compared to literature. The system is closed with one-click fluid disposal bags and markings eliminating the need to pour fluid in to measuring cup. SOMAVAC helps patients and their families recover with dignity after life-impacting surgeries. Significant savings to the hospital and health systems is projected within the immediate $550M market and $4.5B US addressable market. The closed system of fluid collection also allows SOMAVAC to crossover from the medtech to the biotech space potentially advancing science through the analysis of the seroma fluid collected postoperatively from the surgical site. This also extends the total addressable market to $15B. ***** Would this bring value to your medical practice? Investable merits of this company? Let’s discuss in the forum. If you are a physician or healthcare professional with an NPI number, you can register for our private forum to join the discussion. Sign up today! https://mergemedical.community.forum/ ***** DISCLAIMER: Merge Medical and the podcast hosts are providing this content for informational and entertainment purposes only and are not broker dealers or registered investment advisors. We are not providing investment or legal advice. We will bring awareness to interesting projects and companies and then leave further discussion of the clinical and/or investable merits of these companies up to free discussion within the forum. Additionally, podcast participants (including the hosts) and Merge Medical forum members may or may not have a financial interest within the companies being interviewed or featured.
S1 · E20
12 gen 2024
54:23
2 di 4